This Is An (EARLY) Once-In-A-Lifetime Opportunity

Key Concepts

• Base Editing: A precise gene-editing technique that corrects single-letter DNA mutations without cutting both strands of the DNA helix.
• In Vivo vs. Ex Vivo: In vivo involves editing genes directly inside the patient’s body; ex vivo involves removing cells, editing them in a lab, and re-infusing them.
• Drone-as-a-Service (DaaS): A subscription-based business model where companies provide drone operations, maintenance, and regulatory compliance rather than selling hardware.
• NDAA Compliance: Regulations requiring defense-related technology to be manufactured in the U.S. or allied nations, excluding Chinese-made components.
• Capex Rotation: The shift of investment capital from non-AI sectors into AI-related infrastructure, often causing temporary undervaluation in other high-growth industries.

---

Beam Therapeutics (BEAM): The Biotech Value Opportunity

1. Core Technology and Innovation

Beam Therapeutics is pioneering "base editing," a method described as a "molecular pencil" compared to CRISPR’s "molecular scissors." While CRISPR cuts both strands of DNA, potentially causing unpredictable repairs, base editing targets and corrects a single incorrect DNA letter (A, C, G, or T) with higher precision and safety.

2. Key Milestones and Validation

• Clinical Breakthrough: In March 2025, Beam achieved the first-ever clinical correction of a disease-causing mutation in a living human via a single IV infusion.
• Intellectual Property Moat: The company was co-founded by David Liu (inventor of base editing) and Feng Zhang (a pioneer of CRISPR). They hold foundational patents, forcing competitors to either license their technology or struggle to innovate around it.
• Big Pharma Partnerships: Beam has secured validation from industry giants:
  • Pfizer: Liver editing collaboration.
  • Eli Lilly: Cardiovascular work (via Verve Therapeutics).
  • Appelis: Immune system disease research.

3. Financial Context and Catalysts

Despite a 322% year-over-year revenue increase, the stock is down approximately 72% from its all-time high. The speaker attributes this to the "AI capex boom" draining liquidity from the biotech sector.

• Upcoming Catalysts:
  • H2 2026: In vivo data release (expected 20–35% volatility).
  • Late 2026: BLA (Biologics License Application) filing for sickle cell therapy (expected 8–20% impact).
  • July 2026: Trial starts and data updates (expected 5–15% impact).
• Risk Factors: Cash burn, potential shareholder dilution, and the inherent volatility of small-cap biotech stocks.

---

Zenitech (ZNA): The "Netflix of Drones"

1. Market Opportunity

The global DaaS market is projected to grow at over 36% annually through 2034. A critical catalyst is the U.S. government’s effective ban on new Chinese-made drones (which previously held 70–90% of the U.S. market), creating a massive supply vacuum for domestic manufacturers.

2. Business Model and Strategy

Zenitech operates a "Drone-as-a-Service" model, removing the burden of hardware costs, pilot licensing, and FAA compliance from the client.

• Acquisition Playbook: Instead of building from scratch, Zenitech acquires profitable service businesses (e.g., land surveying, infrastructure inspection) and upgrades them with their proprietary AI-driven drone technology.
• Operational Scale: Currently operating 19 U.S. locations, with a target of 25 by mid-2026.

3. Technology and Defense Push

• Hardware: Flagship products include the Zena Drone 1000 (VTOL, 40kg lift) and the IQ series (mapping and indoor scanning).
• Defense Integration: The company is pursuing "Green UAS" and "Blue UAS" certifications to qualify for U.S. Department of Defense contracts. They are expanding a manufacturing facility in Mesa, Arizona, to meet NDAA compliance standards.
• AI Division: A specialized unit in Baton Rouge focuses on autonomous navigation and real-time decision-making analytics for defense applications.

4. Risks

• Profitability: The company is currently in a growth stage and is not yet profitable.
• Execution: Aggressive acquisition strategies require significant capital, which may lead to future dilution.
• Competition: The defense sector is highly competitive and has long, complex procurement cycles.

---

Synthesis and Conclusion

The speaker argues that both Beam Therapeutics and Zenitech represent "asymmetric upside" opportunities currently overlooked by a market obsessed with AI data center infrastructure.

• Beam Therapeutics is presented as a long-term compounder due to its proprietary, first-in-class gene-editing platform and strong institutional validation.
• Zenitech is positioned as a tactical play on domestic manufacturing and the shift toward subscription-based industrial services, bolstered by favorable regulatory tailwinds in the defense sector.

Investors are cautioned that both companies are small-cap, volatile, and carry significant execution risks, necessitating thorough individual due diligence.